Goldman Sachs’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-28,200
Closed -$938K 5651
2020
Q2
$938K Buy
+28,200
New +$898K ﹤0.01% 3996
2018
Q3
Sell
-3,100
Closed -$63K 5908
2018
Q2
$63K Sell
3,100
-1,100
-26% -$23.6K ﹤0.01% 5304
2018
Q1
$76K Hold
4,200
﹤0.01% 5367
2017
Q4
$59K Sell
4,200
-5,400
-56% -$73K ﹤0.01% 5906
2017
Q3
$178K Sell
9,600
-20,500
-68% -$343K ﹤0.01% 5818
2017
Q2
$509K Buy
30,100
+18,200
+153% +$277K ﹤0.01% 5086
2017
Q1
$159K Sell
11,900
-1,000
-8% -$15.7K ﹤0.01% 5847
2016
Q4
$194K Buy
12,900
+1,500
+13% +$19.8K ﹤0.01% 5789
2016
Q3
$133K Buy
11,400
+2,200
+24% +$25.9K ﹤0.01% 6080
2016
Q2
$99K Sell
9,200
-41,700
-82% -$430K ﹤0.01% 6134
2016
Q1
$470K Sell
50,900
-17,400
-25% -$187K ﹤0.01% 4801
2015
Q4
$1.01M Sell
68,300
-122,600
-64% -$2.05M ﹤0.01% 4281
2015
Q3
$3.13M Buy
190,900
+103,700
+119% +$2.12M ﹤0.01% 3337
2015
Q2
$1.99M Buy
87,200
+4,600
+6% +$91.6K ﹤0.01% 3826
2015
Q1
$1.26M Buy
82,600
+49,900
+153% +$648K ﹤0.01% 4243
2014
Q4
$394K Sell
32,700
-52,800
-62% -$603K ﹤0.01% 5510
2014
Q3
$970K Buy
85,500
+6,400
+8% +$73K ﹤0.01% 4642
2014
Q2
$956K Sell
79,100
-30,500
-28% -$360K ﹤0.01% 4730
2014
Q1
$1.28M Sell
109,600
-49,800
-31% -$843K ﹤0.01% 4426
2013
Q4
$2.82M Sell
159,400
-117,900
-43% -$1.98M ﹤0.01% 3711
2013
Q3
$3.99M Buy
277,300
+174,600
+170% +$2.67M ﹤0.01% 3177
2013
Q2
$1.55M Buy
+102,700
New +$1.36M ﹤0.01% 3966

Goldman Sachs's MNTA Position: Q4 2020 in Review

Goldman Sachs sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 1,610,731 shares — an estimated $84.5M sold.

Goldman Sachs first reported a position in MNTA in Q2 2013 and held it in 30 quarters. The position peaked at $84.5M in Q3 2020. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.

  • Goldman Sachs reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Goldman Sachs sold 1,610,731 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $84.5M.
  • Goldman Sachs first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 30 quarters.
  • Goldman Sachs's Momenta Pharmaceuticals, Inc. position peaked at $84.5M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.

Based on Goldman Sachs's 13F filing for Q4 2020, filed 12 Feb 2021.